PCVX Vaxcyte Inc

$PCVX Phase 3 data here tomorrow. Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate "will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia."

$PCVX TAM is huge for this. Company/product family 2025 sales Pfizer Prevnar family $6.49bn Merck Capvaxive $759M Merck Vaxneuvance $825M Merck Pneumovax 23 $166M Global PCV market ~$8.5bn

What do we have for highlights here? $PCVX $OLOX $VCIG $VEEA $KOD to name a few. Whats next? Link in bio for more. All trading and investing involves a risk of loss. Do your own due diligence always!

$PCVX how cubie know pcvx aint gonna pull $MRNA $KOD and go up 150-200% like.the useless pumptards thought. cubie teaches

$PCVX Ugly puking, down 34% from premarket high...remembers me of $MLTX puking on jun 26 of 2023, it went to 103 in premarket to open at about 50...since then is total shit.

$PCVX Definitely pretty impressive but, from my experience it has a lot to do with who the book runners are

$PCVX Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

$PCVX - wants to go back through 75$…. Market needs a good broad pump… not just the large megas… choppy waters now- hard to hold gains …. Like this ling term but not in it for that- good luck!

$PCVX this stupid tard watched it go from 50s to 108. thank god no one was stupid enough to short it on 9/15 when u said so. smart peeps followed cubie treasure trove and shorted it yesterday in $80-$90.

$PCVX it’s back at where is was before that Phrase 3 PR lmao 🤣………… nothing really happen except they stole $1,000,000,000 from investors hahah. Wow I thought all micro cap fraud scam stocks only does that. But PCVX a billion$ market cap company are doing the same scam moves like small micro cap scam stocks doing hahhahahaha. $60…40 sooon im sorry smh

$PCVX Problems with serotypes 3, 4, 12F, 19F and 22F, consistency manufacturing, coverage not as good as capvaxive, will struggle against Pfizer and Merck.

$PCVX that didn't take long Vaxcyte commenced a $500M common stock and pre-funded warrant offering plus $500M of convertible senior notes due 2032, each with a $75M upsize option. Proceeds fund the rest of the VAX-31 adult and infant programs, manufacturing scale-up and U.S. launch prep.

$PCVX burning $$$ and this isn't approval - best p&d today .....sub 50 soon due to heavy shorting ;)

$PCVX I've got my buy stop already set. But for all the bulls out there or anyone thinking of entering long; please read their last quarterly statement. They are burning through cash AND have an active ATM program with a history of using it in the open market. They don't need to file to dilute and they need cash.

$PCVX PCVX is still a clinical-stage biotech with no approved VAX-31 product and significant regulatory/commercial execution ahead

$PCVX My favorite Press Release today: Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate On watch to see if we can have a $MRNA like move from last month!

$PCVX congrats to longs on the convincing phase 3 data win 👏 All primaries met, even superiority on a few STs. Good for sector sentiment $XBI Have to give credit to as well, for sticking to his convictions as usual & laying his thesis out ahead of time. Respect

$PCVX is active on clinical trial results following a Globe Newswire release. Vaxcyte's VAX-31 pneumococcal vaccine met all primary endpoints in Phase 3 OPUS-1 trial, showing noninferiority to competitors with superior immune response for unique serotypes. RTPR pushed this release out to users at 6:00:00 AM ET

$PCVX Monday's biotech winner is Tuesday's example. Vaxcyte fell 9.7 percent to 66.70 Tuesday after the OPUS-1 Phase 3 topline sent it up about 57 percent in morning trading Monday (Reuters). The data was the event, and the event is over. VAX-31 met its primary endpoints, with immune responses at least comparable to Pfizer's Prevnar 20 and Merck's Capvaxive across the 28 shared serotypes, and stronger on the three strains only it covers. Jefferies called it the "blue-sky" case for a 3 billion to 6 billion dollar adult market. But the group is in a two-month slide. The development-biotech cohort fell 3.3 percent Tuesday and has been falling since the August cancer-vaccine peak, per IBD. Two more Phase 3 readouts land in the first half of 2027.

$PCVX Price: $66.7 Volume: Above average Catalyst: Ongoing VAX-31 pivotal trial updates and anticipation of pneumococcal vaccine data keep speculative interest elevated. Resistance: $72 Support: $62 Bull case: A clean break above $72 on strong volume could fuel a run toward prior highs as traders price in trial optimism. Bear case: Failure to hold $62 support may trigger a slide toward $55 if momentum fades and profit-taking kicks in. What I'm watching: Watching for a decisive close above $72 with sustained volume to confirm bullish continuation. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services.